Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 10Lymphoid 7Breast 4Sarcoma 3Plasma cell 3Other hematologic neoplasm 2Tumor-Agnostic 1Myeloid 1Genitourinary 1Dermatologic 1

Conditions

Neoplasm Metastasis 1

Interventions

Specimen Handling 19Biopsy 18Magnetic Resonance Spectroscopy 12Paclitaxel 9trastuzumab deruxtecan 4olaparib 4X-Rays 4Taxes 4nilotinib 3Radiotherapy 3Gemcitabine 3Cisplatin 3Carboplatin 3Bevacizumab 3trametinib 2talazoparib 2pembrolizumab 2omipalisib 2durvalumab 2copanlisib 2aldesleukin 2Vincristine 2Topotecan 2Phantoms, Imaging 2Leucovorin 2Immunoglobulin G 2Fluorouracil 2Doxorubicin 2Disulfides 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × liposomal doxorubicin × Tumor-Agnostic × Clear all
NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡